ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial for its innovative cell therapy, CNK-UT002. This marks a significant milestone, as CNK-UT002 is the first universal cell therapy for solid tumors to be approved for trials in China. The therapy leverages ST Phi’s proprietary CNK-UT technology, which integrates CNK-T and U-T platform technologies, to create a treatment that can potentially target a broad range of tumors with precision. CNK-UT002 works by harnessing the body’s T cells and NK cells, endowing them with the ability to specifically recognize and eliminate various solid and hematological tumors, including liver cancer, melanoma, colorectal cancer, kidney cancer, and T-cell leukemia. The therapy’s potential to address such a wide spectrum of cancers positions it as a promising candidate in the field of oncology.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
